PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.01
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$281.81

23 Oct
2025

-2.580

OPEN

$281.00

-0.91%

HIGH

$283.89

107,653

LOW

$278.02

TARGET
$322.767 14.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 110.3 153.0 xxx
DPS (cps) xxx 55.0 76.6 xxx
EPS Growth xxx 39.1% 38.8% xxx
DPS Growth xxx 37.5% 39.3% xxx
PE Ratio xxx N/A 184.1 xxx
Dividend Yield xxx N/A 0.3% xxx
Div Pay Ratio(%) xxx 49.9% 50.1% xxx

Dividend yield today if purchased 3 years ago: 1.05%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.20

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 22c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx110.3
DPS All xxxxxxxxxxxxxxx55.0
Sales/Revenue xxxxxxxxxxxxxxx213.0 M
Book Value Per Share xxxxxxxxxxxxxxx246.0
Net Operating Cash Flow xxxxxxxxxxxxxxx118.9 M
Net Profit Margin xxxxxxxxxxxxxxx54.10 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx51.82 %
Return on Invested Capital xxxxxxxxxxxxxxx51.46 %
Return on Assets xxxxxxxxxxxxxxx38.65 %
Return on Equity xxxxxxxxxxxxxxx51.82 %
Return on Total Capital xxxxxxxxxxxxxxx70.24 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx69.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx209 M
Price To Book Value xxxxxxxxxxxxxxx115.89

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx7.4 M
Capex % of Sales xxxxxxxxxxxxxxx3.46 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

19/08/2025

3

Hold

$305.00

8.23%

Pro Medicus reported better-than-expected FY25 results, with 2H25 margin of 76% versus Ord Minnett's forecast of 74%.

The analyst liked the addition of a digital pathology platform into its Visage software, which is considered a good strategy as it assists in increasing the company's competitive position versus rivals and peers.

Pro Medicus estimates around 5%-7% of the US healthcare market uses digital pathology systems.

Ord Minnett has lowered its EPS forecasts by -4.3% and -3.9% for FY26 and FY27, respectively, due to lower examination volume assumptions in 2H25. The downgraded earnings still reflect nearly 40% EPS growth from FY25 to FY28 annually.

Hold rating retained, with $305 target unchanged.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Moelis

17/09/2025

3

Hold

$325.82

15.62%

Pro Medicus plans to launch a Visage pathology solution by end-2025, with Moelis highlighting the move as a step towards enterprise imaging.

Only a fraction of pathology is digital today, explains the broker, and while test volumes are large, it's expected the market opportunity will remain smaller than radiology.

Pathology revenues are not included in the analyst's forecasts, with FY26 estimates trimmed for slower ramp-up of large contracts and a cautious view on new wins.

The broker sees pathology as incremental growth, while Pro Medicus continues to trade on a valuation premium supported by strong management, strategy, and passive inflows. Moelis retains a Hold rating and $325.82 target.

FORECAST
Moelis forecasts a full year FY26 dividend of 77.00 cents and EPS of 151.70 cents.
Moelis forecasts a full year FY27 dividend of 94.00 cents and EPS of 193.00 cents.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Weekly Ratings, Targets, Forecast Changes – 17-10-25

Oct 20 2025 - Weekly Reports
2
Next Week At A Glance – 13-17 Oct 2025

Oct 10 2025 - Weekly Reports
3
Rudi’s View: All Eyes On Corporate Results

Oct 08 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
5
Rudi’s View: AI Boom Reveals Our Inner Bias

Oct 01 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
2
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
3
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
4
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
5
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
6
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
7
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
8
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
9
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
10
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia